Ipca Labs hits all-time high of Rs 914; soars 5% in weak market Posted on 8th March 2019 |
.jpg) |
Shares of Ipca Laboratories hit an all-time high of Rs 914, up 5 per cent on the BSE in an otherwise weak market on expectation of strong earnings and margin improvement by going forward. The stock surpassed its previous high of Rs 907 touched on February 28, 2014 in intra-day trade. At 01:11 pm; the benchmark S&P BSE Sensex was trading 0.25 per cent or 93 points lower at 36,632 on the BSE.
Ipca Laboratories had posted healthy operational performance in December 2018 quarter (Q3FY19). The company’s Ebitda (earnings before interest, taxation, depreciation and ammortisation) margin before forex gain was expanded by 385 basis points (bps) at 22.48 per cent in Q3FY19 from 18.63 per cent in Q3FY18. The company's net profit increased 52 per cent year-on-year (YoY) to Rs 160 crore, while net total income grew 10 per cent at Rs 960 crore on YoY basis.
Ipca is a pharmaceutical company with a strong thrust on exports which now account for about 46 per cent of Company's income. The company is vertically integrated and products finish dosage forms and active pharmaceutical ingredients.
IPCA saw strong margin improvement in FY19, aided by the USD-INR tailwinds, higher contribution from domestic business and better product mix in the non-US generics.
Analysts at Elara Capital believe margin will improve by around 310bp over FY19-21E to 22.3 per cent, driven by improved utilization of facilities along with lower remediation cost post FDA clearance, higher institutional business bolstered by injectables and DT launches, ramp-up in the UK and branded generics sales. Given Ipca has zero shipments to the US, but have incurred expenses of Rs 130 crore in the form of remediation, plant running cost and ANDA maintenance fees.
“Resumption of broad-based revenue growth except for the US after flat FY14-18 (vs 13 per cent over FY18-21E) should result in higher operating leverage. Further, strong API capabilities and diversified model are advantages under the current environment,” the brokerage firm said in a company update with reiterate ‘buy’ rating and new target price of Rs 1,040 from 975.
In past one month, Ipca Labs outperformed the market by surging 25 per cent, against a marginal 0.1 per cent rise in the S&P BSE Sensex. |
|
|
|
|
Bharti Airtel defers Q2 results till Nov 14 over ambiguity on AGR verdict Posted on 29th October 2019 |
.jpg) |
Bharti Airtel said on Tuesday it has postponed its second-quarter earnings report to mid-November, as the wireless operator sought clarity on the court ruling asking telecom firms to cough up overdue payments to the government.
Shares of the company, which was expected to release its quarterly numbers later in the day, dropped 3.3 per cent in early trade. |
|
|
Rupee slips 8 paise vs US dollar in early trade amid drop in oil prices Posted on 7th October 2019 |
.jpg) |
The rupee on Monday opened eight paise lower at 70.96 against the US dollar amid drop in crude oil prices and rise in Asian equities. The domestic unit on Friday closed almost flat at 70.88 against after the Reserve Bank of India (RBI) in a widely expected move cut key interest rates by 0.25 percentage point. On a weekly basis, the local unit slumped by 32 paise. |
|
|
LIC pips private insurers in first-year premium growth during April-August Posted on 13th September 2019 |
.jpg) |
In the first five months of the current financial year, first-year premiums of life insurance companies grew by 39.84% (year-on-year) at Rs 1.05 lakh crore as compared to Rs 75,588.35 crore in April-August of 2018-19. Life Insurance Corporation of India (LIC) continued to grow at a faster pace compared to private insurance players, shows the data from the Insurance Regulatory and Development Authority of India (Irdai). |
|
|
Apollo Hospitals rules out further stake sale Posted on 13th September 2019 |
.jpg) |
Apollo Hospitals Enterprise (AHEL) has ruled out further dilution of promoters’ stake in the company. The company also said its Rs 1,337-crore stake sale of Apollo Munich Health Insurance with mortgage major HDFC will be concluded by October. Following these stake sales, the promoters’ pledged position will come down from a high of 76% to 54% by October and eventually to 20% by November or December, company sources said here. |
|
|
World trusts India on Kashmir, not us: Pakistan minister Ijaz Ahmed Shah Posted on 13th September 2019 |
.jpg) |
In a major embarrassment for Pakistan and its Prime Minister Imran Khan, the country's Interior Minister Ijaz Ahmed Shah, a retired brigadier, said the international community didn't believe Pakistan's narrative on Kashmir; instead it is India whose version is trusted. |
|
|
|
|
| Be the first person to write a business review for Ipca Labs hits all-time high of Rs 914; soars 5% in weak market |
|
|
|